Panretinal photocoagulation in patients with proliferative diabetic retinopathy maintains a more favorable cost utility compared without intravitreal ranibizumab in patients with and with diabetic macular edema given the marginal visual benefit in intravitreal ranibizumab
“Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy”
Journal of VitreoRetinal Diseases 2019, Vol 3(5) 346-353, Sept/Oct 2019
James Lin, MD, Nicolas A. Yannuzzi, MD, Jonathan S. Chang, MD, Jayanth Sridhar, MD and William E. Smiddy, MD
Full Paper: Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy
Download (92K PDF)
Half-dose photodynamic therapy is superior to high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy, regardless of the presence of focal or diffuse leakage on fluorescein
“Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
Am. J. Ophthalmol 205:1-10, September 2019
Thomas J. Van Rijssen, Elon H.C. Van Dijk, Paula Scholz, Myrte B. Breukink, Rocio Blanco-Garavito, Eric H. Souied, Jan E.E. Keunen, Robet E. MaClaren, Giuseppe Querques, Sascha Fauser, Susan M. Downes, Carel B. Hoyng, and Camiel J.F. Boon
Full Paper: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
Download (113K PDF)
Individualized treat and extend TREX-DME trial for DME resulted in significantly fewer injections and yielded visual and anatomic gains comparable to monthly dosing at 2 years.
Decreasing the treatment burden while providing clinically significant visual and anatomic improvements is of paramount importance.
“Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes”
Am. J. Ophthalmol 202:91-99, June 2019
John F. Payne, Charles C. Wykoff, W. Lloyd Clark, Beau B. Bruce, David S. Boyer, and David M. Brown, For the TREX-DME Study Group
Full Paper: Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
Download (346K PDF)
If you suspect or have patients with Choroideremia, X linked Retinitis Pigmentosa, RP6R or Achromotopsia, we can screen these patients to determine if they are candidates for gene therapy protocols.
If you would like more information please call our office at 800-643-8197 and speak with Norman Radtke, MD or Kevin.
Full Paper: Gene Therapy Protocols
Download (76K PDF)
The findings of this five-year study by the Diabetic Retinopathy Clinical Research Network support either anti-VEGF therapy or panretinal photocoagulation as viable treatment for patients with proliferative diabetic retinopathy.
“Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy”
A Randomized Clinical Trial
JAMA Ophthalmol 136, Vol 10:1138-1148, Oct 2018
Jeffrey G. Gross, MD et al
Full Paper: Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
Download (317K PDF)
Most patients of VMT gained significant functional and anatomical improvements after vitrectomy. Group 1 optical coherence tomography pattern, shorter symptom duration, and younger age are significant predictive factors of better visual outcome.
“Predictive Factors of Visual Outcome for Vitreomacular Traction Syndrome After Vitrectomy”
Retina 38:1533-1540, 2018
Chang-Sue Yang, MD, MHA; Ming-Hung Hsieh, MD; Yu-Fan Chang, MD; Chiao-Yu Wang, MD; Shih-Jen Chen, MD, PhD
Full Paper: Predictive Factors of Visual Outcome for Vitreomacular Traction Syndrome After Vitrectomy
Download (365K PDF)
In a real-world setting, patients with cataracts and wet age-related macular degeneration underwent treatment for age-related macular degeneration fluid and surgery for cataracts. These patients did well postoperatively with no worsening of their neovascular process.
“Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid”
Am. J. Ophthalmol 192:91-97, August 2018
Matthew R. Starr; Michael A. Mahr; Andrew J. Barkmeier; Raymond Iezzi; Wendy M. Smith; Sophie J. Bakri
Full Paper: Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid
Download (201K PDF)
There are no approved drug treatments for autosomal-dominant retinitis pigmentosa.
A study of oral Valproic acid (VPA) does not support the use of VPA in the treatment of autosomal-dominant retinitis pigmentosa.
The lessons learned from a trial of Valproic acid are:
- Rigorous evaluation of drug treatment for retinitis pigmentosa is necessary.
- FDA-approved drugs for other uses can have major adverse effects.
- Patients vary greatly in their rates of progression of retinitis pigmentosa with identical gene mutations.
“Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa”
Lessons Learned from a Trial of Valproic Acid
JAMA Ophthalmol 136:857-858, August 2018
Brian P. Brooks, MD, PhD; Brett Jeffrey, PhD
Full Paper: Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa_08-13-18
Download (113K PDF)